Certified by Founder
Lodge
Odyssey Therapeutics
start up
United States
- Boston, Massachusetts
- 06/12/2023
- Series C
- $101,000,000
At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
- Industry Biotechnology Research
- Website https://www.odysseytx.com/
- LinkedIn https://www.linkedin.com/company/odyssey-tx/about/
Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)